• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>International Journal of Radiation Oncology, Biology, Physics >Weight gain in advanced non-small-cell lung cancer patients during treatment with split-course concurrent chemoradiotherapy is associated with superior survival.
【24h】

Weight gain in advanced non-small-cell lung cancer patients during treatment with split-course concurrent chemoradiotherapy is associated with superior survival.

机译：分期同步放化疗期间晚期非小细胞肺癌患者的体重增加与较高的生存率相关。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: Preoperative concurrent chemoradiotherapy (CRT) is an accepted treatment for potentially resectable, locally advanced, non-small-cell lung cancer (NSCLC). We reviewed a decade of single institution experience with preoperative split-course CRT followed by surgical resection to evaluate survival and identify factors that may be helpful in predicting outcome. METHODS AND MATERIALS: All patients treated with preoperative split-course CRT and resection at Rush University Medical Center (RUMC) between January 1999 and December 2008 were retrospectively analyzed. Endpoints included overall survival (OS), progression-free survival (PFS), local-regional progression-free survival (LRPFS), and distant metastasis-free survival (DMFS). Patient and treatment related variables were assessed for correlation with outcomes. RESULTS: A total of 54 patients were analyzed, 76% Stage IIIA, 18% Stage IIIB, and 6% oligometastatic. The pathologic complete response (pCR) rate was 31.5%, and the absence of nodal metastases (pN0) was 64.8%. Median OS and 3-year actuarial survival were 44.6 months and 50%, respectively. Univariate analysis revealed initial stage (p < 0.01) and percent weight change during CRT (p < 0.01) significantly correlated with PFS/OS. On multivariate analysis initial stage (HR, 2.4; 95% CI, 1.18-4.90; p = 0.02) and percent weight change (HR, 0.79; 95% CI, 0.67-0.93; p < 0.01) maintained significance with respect to OS. There were no cases of Grade 3+ esophagitis, and there was a single case of Grade 3 febrile neutropenia. CONCLUSIONS: The strong correlation between weight change during CRT and OS/PFS suggests that this clinical parameter may be useful as a complementary source of predictive information in addition to accepted factors such as pathological response.
机译：背景：术前同时放化疗（CRT）是一种潜在可切除的局部晚期非小细胞肺癌（NSCLC）的公认治疗方法。我们回顾了十年前在单机构使用CRT术，然后进行手术切除的经验，以评估生存率并确定有助于预测结局的因素。方法和材料：回顾性分析了1999年1月至2008年12月在拉什大学医学中心（RUMC）接受术前CRT切除术的所有患者。终点包括总生存期（OS），无进展生存期（PFS），局部区域无进展生存期（LRPFS）和远处无转移生存期（DMFS）。评估与患者和治疗相关的变量与结果的相关性。结果：共分析了54例患者，其中76％的IIIA期，18％的IIIB期和6％的低转移。病理完全缓解（pCR）率为31.5％，无淋巴结转移（pN0）为64.8％。 OS的中位数和3年的精算生存率分别为44.6个月和50％。单因素分析显示，初始阶段（p <0.01）和CRT期间体重变化百分比（p <0.01）与PFS / OS显着相关。在多变量分析中，初始阶段（HR，2.4; 95％CI，1.18-4.90; p = 0.02）和体重变化百分比（HR，0.79; 95％CI，0.67-0.93; p <0.01）相对于OS保持显着性。没有3级以上的食管炎病例，只有3级的发热性中性粒细胞减少症。结论：CRT和OS / PFS期间体重变化之间的密切相关性表明，该临床参数除可以接受的因素（例如病理反应）外，还可以作为预测信息的补充来源。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号